2020 Revenues ($USD) : $43,537,603,200
2020 Revenues (foreign currencies) : £34,099,000,000
2020 R&D spend : $6,509,126,400
2020 Number of Employees : 94,066
Fiscal Year End : 12/31/2020
Key People : Dame Emma Walmsley, CEO; Iain Mackay, CFO; Dr. Hal Barron, chief scientific officer and president of R&D; Roger Connor, president, Global Vaccines; Diana Conrad, SVP, human resources; James Ford, SVP and general counsel; Nick Hirons, SVP, Global Ethics and Compliance; Sally Jackson, SVP, global communications and CEO Office; Brian McNamara, CEO, GSK Consumer Healthcare; Luke Miels, president, Global Pharmaceuticals; David Redfern, chief strategy officer; Regis Simard, president, Pharmaceuticals Supply Chain; Karenann Terrell, chief digital & technology officer; Phil Thomson, president, Global Affairs; Deborah Waterhouse, CEO of ViiV Healthcare

GlaxoSmithKline makes over 70 drugs for a broad range of conditions ranging from antidepressants to amoxicillin to oncology drugs. The Brentford, U.K.–based company has worked on COVID-19 vaccine candidates throughout the pandemic. In May 2020, GlaxoSmithKline said it would produce 1 billion doses of adjuvanted COVID-19 vaccine candidates. It signed an agreement along with Sanofi with the U.K. government in July to supply 60 million doses of a vaccine in the U.K. GlaxoSmithKline has also been working with Medicago to develop a plant-derived COVID-19 vaccine candidate and announced the beginning of a Phase 3 trial in March this year. The company in February this year said it would support the manufacturing of up to 100 million doses of CureVac's first-generation vaccine candidate throughout this year. –DK